The Omicron variant and the stock market

In This Article:

This article first appeared in the Morning Brief. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET. Subscribe

Monday, November 29, 2021

I am not a doctor. I will venture to say that most of you reading this aren't doctors, either.

So all we could collectively do after Friday's market beatdown is assess incoming information on the Omicron variant to the best of our ability and go from there.

Here's the current state of play in this fast-changing COVID-19 news cycle:

  • Moderna thinks it may be able to develop a new vaccine to fight the Omicron variant by early 2022. “If we have to make a brand new vaccine I think that’s going to be early 2022 before that’s really going to be available in large quantities,” said Paul Burton, Moderna's chief medical officer, in a Sunday BBC interview. Moderna stock was up 20% on Friday. Hot take: I think this commentary may alleviate a little of the angst among medium to longer-term investors, with the emphasis on a little.

  • Dr. Anthony Fauci told "Face the Nation" on Sunday the U.S. "has the potential to go into a fifth wave" of the pandemic. Hot take: Obviously worrisome, and will only fuel the near-term bearish narrative.

  • Travel restrictions are on the rise from developed economies as officials run their COVID-19 protection playbooks. CNN has a solid breakdown of where the travel bans have kicked in. Hot take: Here comes talk of lockdowns. "If border restrictions are not effective and variant characteristics are as bad as some fear, there is risk more lockdowns will be needed to avoid overrunning health systems, at the very least in affected regions. Some health departments may lean towards taking early precautionary action to avoid much greater economic risks down the track," points out JPMorgan's research team.

  • On Sunday, Germany and Italy confirmed their first Omicron cases. Hot take: Those reports will feed the short-term bear take that COVID mutations are spreading quickly and are resistant to current vaccines.

In the near-term, we are likely to witness a sell first, ask questions later type of backdrop for the stock market. The bull thesis on stocks — a global economic awakening powered by COVID-19 vaccinations — is temporarily on hold. If you own airline stocks such as Delta Air Lines and JetBlue Airways, more pain is probable. Same goes for hotel stocks Hilton and Marriott. The hedges here are the pandemic plays like Zoom and Moderna.

The S&P 500 entered these latest COVID concerns trading on a P/E ratio two points higher than two years ago. Investors forgot the pandemic is still very much with us, and will be for some time to come. Now these excesses need to be worked off.